Prevention of lymphocele in female pelvic lymphadenectomy by a collagen patch coated with the human coagulation factors: A pilot study

Tinelli, Andrea; Giorda, Giorgio; Manca, Corrado; Pellegrino, Marcello; Prudenzano, R; Guido, Marcello; Dell'Edera, Domenico; Malvasi, Antonio

doi:10.1002/jso.22110

Cited by 25 publications

(32 citation statements)

References 27 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the main indication is intraoperative bleeding in liver or pulmonary resections, TachoSil® has also been studied in women with vulvar cancer after groin dissection [15], pelvic lymphadenectomy by gynecological cancer [10], by prostate cancer [17]; or after axillary dissection by breast cancer [16] to prevent lymphocele formation with encouraging results.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 7 out of 30 (23.3%) women in the treatment group compared to 9 out of 28 (57.7%) women in the control group developed asymptomatic lymphoceles (p < 0.05). However, the incidence of SLC was similar between the 2 groups [10]. …”

Section: Discussionmentioning

confidence: 99%

“…Several strategies to prevent SLC have been described after pelvic lymphadenectomy by using Ligaclip, bipolar energy [9], or more recently, TachoSil® [10]. TachoSil® is a fibrin-collagen coated patch and has been licensed in 2004 in Europe for surgical use in humans to support surgical hemostatic interventions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of TachoSil® to Prevent Symptomatic Lymphocele after an Aggressive Tumor Debulking with Lymphadenectomy for Advanced Stage Ovarian Cancer. A Pilot Study

Minig

Patrono

Cárdenas-Rebollo

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: To describe the incidence of symptomatic lymphocele (SLC) after an aggressive tumor debulking surgery and lymphadenectomy in patients with ovarian cancer and peritoneal carcinomatosis with or without TachoSil®. Material and Methods: A pilot retrospective comparative observational study was performed between patients with advanced ovarian cancer International Federation of Gynecology and Obstetrics stages III-IV who underwent complete debulking surgery and radical retroperitoneal lymphadenectomy. In 18 patients, 4 TachoSil® patches were placed in the retroperitoneal area, since January 2014-October 2014. This group was compared with other 18 consecutive patients matched by age, International Federation of Gynecology and Obstetrics stage, surgical complexity, American Society of Anesthesiologists score, comorbidity, and BMI without the use of TachoSil®. Results: Baseline characteristics were similar between groups. There were no statistically significant differences in terms of surgical complexity, surgical time, estimated blood loss, node removed, length of hospital stay, and complications between groups. SLC was diagnosed in 7 patients (38.8%) without TachoSil®, and in 2 patients (11.1%) with TachoSil® (p = 0.121). The use of TachoSil® was associated with a statistically significant lower re-admission rate (p = 0.041) and with a significantly shorter time to adjuvant chemotherapy (p = 0.02). Conclusions: Using TachoSil® in women with advanced stage ovarian cancer who underwent radical debulking with retroperitoneal lymph node dissection is associated with a non-statistically significant reduction in the incidence of SLC. A larger-scale randomized controlled study should be conducted to confirm our preliminary results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of TachoSil® to Prevent Symptomatic Lymphocele after an Aggressive Tumor Debulking with Lymphadenectomy for Advanced Stage Ovarian Cancer. A Pilot Study

Minig

Patrono

Cárdenas-Rebollo

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Authors have previously addressed the issue of the prevention of lymphocele or lymphocyst after pelvic lymphadenectomy in endometrial cancer after laparotomy through the use of a collagen patch coated with the human coagulation factors, named TachoSil (Nycomed International Management GmbH, Zurich, Switzerland), at the end of pelvic lymphadenectomies. 10 TachoSil is a sterile ready-to-use absorbable patch for intraoperative topical application, which works by mimicking the final steps of the natural blood clotting process, creating a robust fibrin clot at the surgical wound site to achieve hemostasis and sealing in 3 to 5 minutes. TachoSil provides quick, reliable hemostasis by creating a robust fibrin clot adherent to the tissue surface, and it is involved in the sealing of lymphatic capillaries.…”

mentioning

confidence: 99%

Lymphocele Prevention After Pelvic Laparoscopic Lymphadenectomy by a Collagen Patch Coated With Human Coagulation Factors: A Matched Case-Control Study

Tinelli

Mynbaev

Tsin

et al. 2013

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has a large patch of 9.5 cm x 4.8 cm x 0.5 cm, a medium patch of 4.8 cm x 4.8 cm x 0.5 cm and a small patch of 3.0 cm x 2.5 cm x 0.5 cm. At our Hospital, TachoSil is currently available for clinical practice and it is distributed by the hospital pharmacy and this product is currently approved in Europe for supportive haemostatic treatment in surgery, since the efficacy and safety of TachoSil was already demonstrated in many surgeries [17][18][19][20][21].…”

Section: Picturementioning

confidence: 99%

Post-Cesarean Section Hemorrage Treated by a Collagen Patch Coated with the Human Coagulation Factors

Tinelli¹

2011

J Clinic Case Reports

Self Cite

View full text Add to dashboard Cite

Uterine hemorrhage is a common problem at the time and after caesarean section especially in a repeat caesarean section, where the surgical techniques used widely differ. An inadequate hemostasis of the uterine incision and the vesical-uterine vessels during CS, in closed and open visceral peritoneum, could lead to early hemorrhagic compliances, to control by further surgery.We present the case of a 31 year old woman undergoing a scheduled repeat emergency caesarean section. She had progressive bleeding from the incision site during the first post-operative days, since in third day she developed a hemorrhagic shock for a hemoperitoneum. Patient was re-operated and bleeding at uterine site incision was not controlled by traditional management including intravenous oxytocin and ergometrine, intramyometrial ergometrin and local hemostatic sutures, but was successfully controlled by equine collagen patch coated with human coagulation factors. Her post operative period was uneventful and she and her baby were discharged in good condition on day 5. Both of them were doing well on a follow up visit after 1 month.

show abstract

Prevention of lymphocele in female pelvic lymphadenectomy by a collagen patch coated with the human coagulation factors: A pilot study

Abstract: Intraoperative application of TachoSil reduced rate of postoperative lymphocysts after PL, and it seems to provide a useful additional treatment option for reducing drainage volume and preventing lymphocele development after PL.

Cited by 25 publications

References 27 publications

Use of TachoSil® to Prevent Symptomatic Lymphocele after an Aggressive Tumor Debulking with Lymphadenectomy for Advanced Stage Ovarian Cancer. A Pilot Study

Use of TachoSil® to Prevent Symptomatic Lymphocele after an Aggressive Tumor Debulking with Lymphadenectomy for Advanced Stage Ovarian Cancer. A Pilot Study

Lymphocele Prevention After Pelvic Laparoscopic Lymphadenectomy by a Collagen Patch Coated With Human Coagulation Factors: A Matched Case-Control Study

Post-Cesarean Section Hemorrage Treated by a Collagen Patch Coated with the Human Coagulation Factors

Contact Info

Product

Resources

About